BCMA CD3 BiTE - Google News

ASCO GU: J&J plays up precision therapy approach for Zejula's prostate cancer bid after mixed results - FiercePharma

over 3 years ago

ASCO GU: J&J plays up precision therapy approach for Zejula's prostate cancer...

Tiziana rethinks oral antibody trial amid feasibility problems - FiercePharma

over 3 years ago

Tiziana rethinks oral antibody trial amid feasibility problems  FiercePharma

J&J goes after another FDA approval for a cancer bispecific - - pharmaphorum

over 3 years ago

J&J goes after another FDA approval for a cancer bispecific -  pharmaphorum

Spotlighting Key Therapies in the Oncology Pipeline for the First Half of 2022 - AJMC.com Managed Markets Network

over 3 years ago

Spotlighting Key Therapies in the Oncology Pipeline for the First Half of...

ASH 2021: What to look out for from pharma and biotech - The Pharma Letter

over 3 years ago

ASH 2021: What to look out for from pharma and biotech  The...

Mitigating Toxicities Will Position BCMA for Role in Triple-Class Refractory Multiple Myeloma - OncLive

over 3 years ago

Mitigating Toxicities Will Position BCMA for Role in Triple-Class Refractory Multiple Myeloma...

AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting - Yahoo Finance

over 3 years ago

AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology...

mAbs in multiple myeloma: first-to-market advantage will be strong - Clinical Trials Arena

almost 4 years ago

mAbs in multiple myeloma: first-to-market advantage will be strong - pharmaceutical-technology.com

almost 4 years ago

mAbs in multiple myeloma: first-to-market advantage will be strong - pharmaceutical-technology.com

almost 4 years ago

Targeting CD38/CD3 in the immunotherapy of Multiple Myeloma - News-Medical.net

almost 4 years ago

Treating relapsed and refractory multiple myeloma | CPAA - Dove Medical Press

almost 4 years ago